Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, Poland.
Medical Center Tysiaclecie, Katowice, Poland.
Hum Vaccin Immunother. 2021 Sep 2;17(9):3126-3130. doi: 10.1080/21645515.2021.1913961. Epub 2021 Apr 29.
An observational study of a retrospective cohort was performed to assess the impact of influenza vaccination (IV) on the risk of SARS-CoV-2 infection in a population of middle-aged people for 8 weeks after IV and compared with an unvaccinated group. Data from 1098 middle-aged patients (53.7 ± 4.7 years) after IV and 1205 unvaccinated patients (50.1 ± 6.8 years) were analyzed based on medical documentation. The inclusion criteria were age between 40 - 60 years and IV in the period from 1-30 September 2020. The incidence of infection with SARS-CoV-2 was confirmed by PCR and the classification of ICD-10 (U07.1). After IV, patients had significantly fewer SARS-CoV-2 infections than the unvaccinated patients ( = .017). The hazard ratio was 0.74 (95% CI: 0.54-0.89). IV may partially reduce the risk of SARS-CoV-2 infection.
一项回顾性队列观察研究评估了流感疫苗接种（IV）对中年人群接种后 8 周内感染 SARS-CoV-2 的风险的影响，并与未接种组进行了比较。根据医疗记录，对 1098 名接种后中年患者（53.7±4.7 岁）和 1205 名未接种患者（50.1±6.8 岁）的数据进行了分析。纳入标准为年龄在 40-60 岁之间，且于 2020 年 9 月 1 日至 30 日期间接种 IV。通过 PCR 和 ICD-10（U07.1）分类确认 SARS-CoV-2 感染的发生率。接种 IV 后，患者感染 SARS-CoV-2 的情况明显少于未接种患者（ =.017）。风险比为 0.74（95%CI：0.54-0.89）。IV 可能部分降低 SARS-CoV-2 感染的风险。
